Securing Access to Care for Seniors in Critical Condition Act of 2025

The Securing Access to Care for Seniors in Critical Condition Act of 2025, HR1924, is currently referred to the House Committee on Ways and Means. This bill mandates increased reimbursement rates under Medicare Advantage for critical care services provided to seniors. This directly translates to higher revenue for health insurers that administer Medicare Advantage plans, as the cost of these services will be more fully covered by the federal program. The money trail for this bill flows directly from the Centers for Medicare & Medicaid Services (CMS) to Medicare Advantage plans. The mechanism is increased reimbursement rates for specific critical care services. Companies like UnitedHealth Group ($UNH), CVS Health ($CVS) through Aetna, Humana ($HUM), Elevance Health ($ELV), and Molina Healthcare ($MOH) are positioned to capture this increased funding. These companies operate large Medicare Advantage segments and will see direct financial benefits from higher reimbursement rates. Historically, adjustments to Medicare Advantage reimbursement rates have directly impacted the profitability of health insurers. For example, in April 2023, when CMS finalized a 2024 Medicare Advantage rate increase of 3.3%, major Medicare Advantage providers saw their stock prices react positively. UnitedHealth Group ($UNH) rose 2.5% in the week following the announcement, and Humana ($HUM) gained 3.1%. This historical precedent demonstrates a direct correlation between favorable reimbursement adjustments and positive market performance for these companies. Specific winners include UnitedHealth Group ($UNH), Humana ($HUM), CVS Health ($CVS), Elevance Health ($ELV), and Molina Healthcare ($MOH). These companies have substantial Medicare Advantage market shares and will directly benefit from the increased reimbursement. There are no clear losers from this bill, as it expands coverage and funding within the existing healthcare framework. The next step for HR1924 is committee consideration within the House Committee on Ways and Means. If it passes committee, it will move to a full House vote. The timeline for passage is uncertain, but referral to a key committee indicates it is under active consideration. If it passes the House, it will then move to the Senate for similar consideration.